Late clinical outcomes of myocardial hybrid revascularization versus coronary artery bypass grafting for complex triple-vessel disease: Long-term follow-up of the randomized MERGING clinical trial.
Vinicius EstevesMarco A P OliveiraFernanda S FeitosaJosé MarianiCarlos M CamposLudhmila A HajjarLuiz A LisboaFabio B JateneRoberto K FilhoPedro Alves Lemos NetoPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2020)
Hybrid myocardial was feasible but associated with increasing rates of major adverse cardiovascular events during 2 years of clinical follow-up, while the control group treated with conventional surgery presented with low rates of complications during the same period. In conclusion, before more definitive data arise, hybrid revascularization should be applied with careful attention in practice, following a selective case-by-case indication.
Keyphrases
- coronary artery bypass grafting
- coronary artery disease
- cardiovascular events
- percutaneous coronary intervention
- clinical trial
- double blind
- coronary artery bypass
- open label
- left ventricular
- minimally invasive
- phase ii
- phase iii
- healthcare
- primary care
- acute coronary syndrome
- working memory
- electronic health record
- type diabetes
- emergency department
- locally advanced
- quality improvement
- atrial fibrillation
- risk factors
- newly diagnosed
- radiation therapy
- deep learning
- adverse drug
- surgical site infection